BioNTech Charts New Course: Founder Exit, ASCO Showdown, and a $20 Billion War Chest

They built a company that delivered the first mRNA COVID-19 vaccine, and now Ugur Sahin and Özlem Türeci are preparing to walk away. At the annual general meeting on May 15, Sahin delivered what amounted to a farewell address, telling shareholders that the pair will hand over operational control by the end of 2026 to lead a new venture. The symbolic gesture – delivered before 92% of the share capital – marks the end of an era for the Mainz-based biotech and the beginning of its transition from a pure vaccine powerhouse into a diversified oncology player.

The market, however, is biding its time. BioNTech’s stock has slipped to €76.20, more than 12% below its 200-day moving average. At around €77, it trades nearly 11% lower than a year ago and remains a long way from its 52-week high of €101.90 reached in the summer of 2025. Daina Graybosch, an analyst at Leerink Partners, called the leadership change a logical step for a maturing company but warned it injects meaningful uncertainty into a stock already under delivery pressure.

That uncertainty is compounded by a second major event on the near-term horizon. On May 29, at the ASCO conference, BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study, pitting its candidate Pumitamig against pembrolizumab (Keytruda), the current standard of care in lung cancer immunotherapy. A strong showing could fundamentally reshape how investors view the oncology pipeline – but a miss would leave the stock exposed.

A Cash-Rich Pivot at a Cost

The numbers tell the story of a company in transition. BioNTech ended March with nearly $20 billion in cash and has an active share buyback program, yet it posted a net loss in the first quarter after pumping more than $650 million into research and development. Vaccine revenue came in at just $138 million. The company is willing to absorb those losses to fund its oncology ambitions, and shareholders have given it the tools to do so: the AGM approved a capital increase authorization of up to 50% of existing shares, a move analysts see as strategic flexibility for potential acquisitions or partnerships rather than a sign of distress.

Should investors sell immediately? Or is it worth buying BioNTech?

Cost discipline is also part of the plan. BioNTech will close sites in Idar-Oberstein, Marburg, and Tübingen by the end of next year, and exit its Singapore manufacturing operation in the first quarter. From 2029, these measures are expected to generate annual savings of up to €500 million.

Fresh Faces on the Board and a Deep Pipeline

The governance overhaul began before the founders’ departure. BioNTech expanded its supervisory board from six to eight members, bringing in Iris Löw-Friedrich and Susanne Schaffert, both respected oncology specialists. The move signals that the company intends to keep its strategic focus on cancer even as it searches for a new CEO and management team.

On the science side, the pipeline is crowding toward late-stage development. BioNTech now plans to run 15 Phase 3 studies by the end of 2026, with seven data readouts from advanced programs expected this year alone. The most advanced individual candidate, the antibody-drug conjugate BNT323 (also known as datopotamab deruxtecan), is on track for a US regulatory filing this year after Phase 2 data showed response rates above 70% in certain endometrial cancer patients. If approved, that drug would give the incoming management a ready-made commercial anchor.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The contractual details of the founders’ exit are being hammered out. BioNTech intends to transfer certain mRNA technologies and rights to the new project in exchange for a minority stake, milestone payments, and royalties. A binding agreement is due by the end of June. Meanwhile, the search for a new leadership team is under way, and the expanded board will oversee that process.

For now, all eyes are on May 29. The ASCO data will either validate the billions being poured into research or raise fresh questions about whether the oncology pivot can deliver on its promise. Either way, BioNTech’s next chapter begins long before Sahin and Türeci finally step away.

Ad

BioNTech Stock: New Analysis - 18 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69364220 |